Last $3.70 USD
Change Today +0.45 / 13.85%
Volume 18.4M
GERN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Open
$3.30
Previous Close
$3.25
Day High
$3.76
Day Low
$3.28
52 Week High
12/6/13 - $6.54
52 Week Low
03/12/14 - $1.31
Market Cap
581.7M
Average Volume 10 Days
9.4M
EPS TTM
$-0.25
Shares Outstanding
157.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GERON CORP (GERN)

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

46 Employees
Last Reported Date: 03/17/14
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $569.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Executive Vice President of Development and T...
Total Annual Compensation: $367.4K
Executive Vice President of Legal Affairs & H...
Total Annual Compensation: $302.2K
Executive Vice President of Business Developm...
Total Annual Compensation: $341.6K
Compensation as of Fiscal Year 2013.

geron corp (GERN) Key Developments

Geron Corporation, Janssen Biotech, Inc. - Special Call

Geron Corporation, Janssen Biotech, Inc. - Special Call

Geron Corporation Announces Audited Consolidated Earnings Results for the Third Quarter and Nine Months of 2014

Geron Corporation announced audited consolidated earnings results for the third quarter and nine months of 2014. For the quarter, the company reported net loss of $9.5 million, or $0.06 per share, compared to $8.3 million, or $0.06 per share, for the comparable 2013 period. Revenues were $160,000 compared to $181,000 for the comparable 2013 period. Interest and other income amounted to $91,000 compared to $699,000 for the comparable 2013 period. The decrease in interest and other income for the third quarter of 2014, compared to the same period in 2013, was primarily the net result of a gain on the sale of excess laboratory equipment in connection with the closure of the company's research laboratory facility in 2013, partially offset by higher interest income due to increased cash and investment balances with the receipt of net cash proceeds from the underwritten public offering the company completed in February 2014. Loss from operations was $9,907,000 against $8,733,000 a year ago. For the nine months, the company reported net loss of $26.7 million, or $0.18 per share, compared to $29.1 million, or $0.23 per share, for the comparable 2013 period. Revenues were $1.0 million compared to $1.1 million for the comparable 2013 period. Interest and other income was $273,000 compared to $836,000 for the comparable 2013 period. The decrease in interest and other income for the first nine months of 2014, compared to the same period in 2013, was primarily the net result of a gain in 2013 for the sale of excess laboratory equipment, partially offset by an increase in interest income in 2014. Loss from operations was $27,301,000 against $29,683,000 a year ago.

Geron Corporation Announces Removal of Full Clinical Hold on Its Investigational New Drug Application by U.S. Food and Drug Administration

Geron Corporation announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on its investigational new drug (IND) application for imetelstat. In addition, the FDA stated that the company’s proposed clinical development plan for imetelstat that is focused on high-risk myeloid malignancies, such as myelofibrosis (MF), is acceptable. The FDA acknowledged that the company does not intend to conduct further studies in, or develop imetelstat for, the treatment of essential thrombocythemia (ET) or polycythemia vera, which is consistent with the company's plans as originally disclosed in April 2013. To address the full clinical hold, the FDA required the company to provide follow-up information from imetelstat-treated patients who experienced liver function test (LFT) abnormalities until such abnormalities resolved to normal or baseline. Geron obtained clinical follow-up information from patients in the previously ongoing company-sponsored Phase 2 trials in ET and multiple myeloma (MM). These data were submitted to the FDA as part of the company's complete response. The company's analysis of these data concluded that in the ET trial LFT abnormalities resolved to normal or baseline in 14 of 18 follow-up patients. For the remaining four ET patients, at the time of the data cut-off, three patients showed improvement in LFT abnormalities and one patient had unresolved LFT abnormalities. Currently, two of the remaining four ET patients continue in follow-up. In the MM trial, LFT abnormalities resolved to normal or baseline in all nine follow-up patients. In addition, no emergent hepatic adverse events were reported during follow-up for either study. The FDA also requested information regarding the reversibility of liver toxicity after chronic imetelstat administration in animals. The company submitted data from its previously conducted non-clinical toxicology studies, which included a six-month study in mice and a nine-month study in cynomolgus monkeys. In these studies, no clinical pathology changes indicative of hepatocellular injury were observed, and no clear signal of LFT abnormalities were identified. With the lift of the full clinical hold, a multi-center Phase 2 clinical trial in MF is projected to begin in the first half of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $3.70 USD +0.45

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.36 USD +0.0005
BioTime Inc $3.11 USD -0.19
IntelliCell BioSciences Inc $0.0002 USD 0.00
Neuralstem Inc $2.78 USD -0.02
ReNeuron Group PLC 3.38 GBp +0.125
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.